Beta Drugs: Driven Towards Delivering A Diverse Range Of Oncology & Comeceuticals Solutions
Rahul Batra, Chairman & Managing Director , Varun Batra, Joint Managing Director
Cancer care is on the cusp of a seismic shift, and India’s pharmaceutical sector is setting the pace. The country has firmly established itself as one of the world’s leading suppliers of affordable, high-quality generics and biosimilars, exporting nearly half its production to major markets like the U.S., U.K., South Africa, and Russia. As the global pharmaceutical market accelerates toward a projected $3 trillion valuation by 2034, Indian manufacturers focus on backward integration, complex drug manufacturing, and regulatory compliance will enable them to capture a larger share of the market. Government initiatives fostering ease of business, coupled with a renewed emphasis on R&D, novel drug delivery systems, and cost-effective therapies, are enabling manufacturers likes Beta Drugs Limited deliver scalable, affordable production to meet rising global demand.
Comprehensive Oncology Portfolio
Beta Drugs is a pharmaceutical manufacturing company that specializes in oncology products and cosmeceuticals. Its journey began in the early 1980s under the visionary leadership of the late Vijay Batra, who recognized the potential in the oncology segment. Over the decades, the company has developed a comprehensive oncology product portfolio comprising 135 SKUs. Its evolution has earned it a reputation as a trusted supplier to more than 50 leading Indian pharmaceutical companies, with a strong presence in 90 percent of corporate and government institutions. “We are a manufacturer of widest range of oncology products in India like liquid injections, lyophilized injections, pre-filled syringes, tablets, capsules, suspensions, and solutions”, says Varun Batra, Joint Managing Director of Beta Drugs. It frequently introduces first-to-market generic oncology products that address specific patient needs while maintaining affordability.
The company has a robust pipeline that includes cytotoxic medicines and targeted therapies, such as PARP inhibitors and novel biological agents. These products are designed with patient safety and efficacy in mind, with each formulation reflecting Beta Drugs’s commitment to providing accessible, cost-effective treatment options. Its emphasis on internal quality assurance is evident in its state-of-the-art manufacturing facilities, which comply with cGMP standards and are approved by inter¬nationally recognized regulatory bodies. This commitment to quality and regulatory compliance reassures clients that every product meets rigorous international standards.
Investing in Innovation & Operational Excellence
It operates with a backward integrated model, producing over 80 percent of its active pharmaceutical ingredients in-house. The strategy guarantees consistent quality and cost-effectiveness and enables the company to meet stringent global regulatory standards through robust quality control, advanced research and development, and efficient client engagement practices. Beta Drugs has invested heavily in upgrading its manufacturing processes, implementing cutting-edge equipment, and maintaining a robust network of suppliers. This investment is reflected in its extensive manufacturing capacity, which supports both large-scale production and the flexibility to meet specialized client demands.
It continues to push the boundaries of innovation by focusing on new drug delivery systems and targeted therapies. Its pioneering work in developing novel formulations, such as albumin-bound paclitaxel and ready-to-use formulations of key oncology drugs. The company’s focus on innovation has allowed it to secure approvals from several international regulatory agencies, which further enhances its credibility with global clients. Clients in the pharmaceutical industry benefit from these innovations through access to therapies that are effective and cost-efficient, ensuring that quality treatment options are available to a broader patient base.
A Client-Centric Manufacturing Excellence
The company maintains dedicated account managers who provide personalized updates and documentation support, from regulatory submissions to audit assistance. Each step of the client engagement process is handled with care, beginning with an in-depth consultation to understand product requirements, market strategies, and regulatory needs. A comprehensive proposal is then developed, outlining product specifications, production timelines, cost structures, and delivery schedules. After formal agreements are in place, production proceeds under continuous quality monitoring.
Beta Drugs provides customized primary and secondary packaging solutions that adhere to rigorous safety and regulatory standards. The company ensures that its packaging is child-resistant and tamper-proof, offers cold chain solutions for temperature-sensitive oncology drugs, and incorporates multilingual labeling to serve international markets effectively. In addition, it collaborates with GMP-certified logistics partners to facilitate seamless cold-chain transportation when required, provide real-time shipment tracking, and secure the necessary regulatory clearances for international distribution. The company continuously analyzes production efficiency and explores cost-reduction strategies without compromising quality. It also maintains regular engagement with its clients, discussing potential product modifications or line extensions, new market expansion strategies, and opportunities for R&D collaborations.
Beta Drugs has expanded its reach beyond India, now operating in over 46 countries, with plans underway to ex¬tend its market presence in Europe. Anticipating the expansion of the oncology market driven by the rising number of cancer patients in India and the transition of many oncology products thunderstorm Beta Drugs remains committed to strengthen its international footprint, particularly in Europe and other semi-regulated regions. The company focuses on advancing novel drug delivery systems and targeted therapies that improve efficacy, safety, and patient compliance. At the same time, its foray into the high-end skincare segment illustrates a strategic effort to diversify and meet emerging market demands. This approach reinforces Beta Drugs’ dedication to innovation, quality, and regulatory compliance, ensuring that it can continue to serve its clients with excellence domestically and on the global stage.
Comprehensive Oncology Portfolio
Beta Drugs is a pharmaceutical manufacturing company that specializes in oncology products and cosmeceuticals. Its journey began in the early 1980s under the visionary leadership of the late Vijay Batra, who recognized the potential in the oncology segment. Over the decades, the company has developed a comprehensive oncology product portfolio comprising 135 SKUs. Its evolution has earned it a reputation as a trusted supplier to more than 50 leading Indian pharmaceutical companies, with a strong presence in 90 percent of corporate and government institutions. “We are a manufacturer of widest range of oncology products in India like liquid injections, lyophilized injections, pre-filled syringes, tablets, capsules, suspensions, and solutions”, says Varun Batra, Joint Managing Director of Beta Drugs. It frequently introduces first-to-market generic oncology products that address specific patient needs while maintaining affordability.
The company has a robust pipeline that includes cytotoxic medicines and targeted therapies, such as PARP inhibitors and novel biological agents. These products are designed with patient safety and efficacy in mind, with each formulation reflecting Beta Drugs’s commitment to providing accessible, cost-effective treatment options. Its emphasis on internal quality assurance is evident in its state-of-the-art manufacturing facilities, which comply with cGMP standards and are approved by inter¬nationally recognized regulatory bodies. This commitment to quality and regulatory compliance reassures clients that every product meets rigorous international standards.
Investing in Innovation & Operational Excellence
It operates with a backward integrated model, producing over 80 percent of its active pharmaceutical ingredients in-house. The strategy guarantees consistent quality and cost-effectiveness and enables the company to meet stringent global regulatory standards through robust quality control, advanced research and development, and efficient client engagement practices. Beta Drugs has invested heavily in upgrading its manufacturing processes, implementing cutting-edge equipment, and maintaining a robust network of suppliers. This investment is reflected in its extensive manufacturing capacity, which supports both large-scale production and the flexibility to meet specialized client demands.
“Beta Drugs has expanded its reach beyond India, now operating in over 46 countries, with plans underway to extend its market presence into Europe
It continues to push the boundaries of innovation by focusing on new drug delivery systems and targeted therapies. Its pioneering work in developing novel formulations, such as albumin-bound paclitaxel and ready-to-use formulations of key oncology drugs. The company’s focus on innovation has allowed it to secure approvals from several international regulatory agencies, which further enhances its credibility with global clients. Clients in the pharmaceutical industry benefit from these innovations through access to therapies that are effective and cost-efficient, ensuring that quality treatment options are available to a broader patient base.
A Client-Centric Manufacturing Excellence
The company maintains dedicated account managers who provide personalized updates and documentation support, from regulatory submissions to audit assistance. Each step of the client engagement process is handled with care, beginning with an in-depth consultation to understand product requirements, market strategies, and regulatory needs. A comprehensive proposal is then developed, outlining product specifications, production timelines, cost structures, and delivery schedules. After formal agreements are in place, production proceeds under continuous quality monitoring.
Beta Drugs provides customized primary and secondary packaging solutions that adhere to rigorous safety and regulatory standards. The company ensures that its packaging is child-resistant and tamper-proof, offers cold chain solutions for temperature-sensitive oncology drugs, and incorporates multilingual labeling to serve international markets effectively. In addition, it collaborates with GMP-certified logistics partners to facilitate seamless cold-chain transportation when required, provide real-time shipment tracking, and secure the necessary regulatory clearances for international distribution. The company continuously analyzes production efficiency and explores cost-reduction strategies without compromising quality. It also maintains regular engagement with its clients, discussing potential product modifications or line extensions, new market expansion strategies, and opportunities for R&D collaborations.
Beta Drugs has expanded its reach beyond India, now operating in over 46 countries, with plans underway to ex¬tend its market presence in Europe. Anticipating the expansion of the oncology market driven by the rising number of cancer patients in India and the transition of many oncology products thunderstorm Beta Drugs remains committed to strengthen its international footprint, particularly in Europe and other semi-regulated regions. The company focuses on advancing novel drug delivery systems and targeted therapies that improve efficacy, safety, and patient compliance. At the same time, its foray into the high-end skincare segment illustrates a strategic effort to diversify and meet emerging market demands. This approach reinforces Beta Drugs’ dedication to innovation, quality, and regulatory compliance, ensuring that it can continue to serve its clients with excellence domestically and on the global stage.
🍪 Do you like Cookies?
We use cookies to ensure you get the best experience on our website. Read more...